Press release
Shingrix (Zostavax) Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities
Shingrix (Zostavax)
What Is the Projected Growth of the Shingrix (Zostavax) Market?
In the past few years, the Shingrix (Zostavax) market has seen a growth of XX (HCAGR). The market, which was worth $XX million in 2024, is projected to further grow to $XX million in 2025, implying a compound annual growth rate (CAGR) of XX%. The historic expansion can be attributed to factors such as elevated adoption of vaccines, the surge in the demand for educational campaigns, increased emphasis on preventive healthcare, enhanced patient education, advocacy initiatives, and an uptick in insurance coverage for immunization.
In the upcoming years, the market size of Shingrix (Zostavax) is predicted to experience a XX% rise (FCAGR). By 2029, this market is projected to escalate to $XX million with an annual compound growth rate (CAGR) of XX%. This growth during the forecast period can be linked to factors such as an aging population, heightened instances of herpes zoster and chickenpox, an increase in disease prevalence, and a growing awareness of shingles and its potential complications. The forecast period will also see developments such as innovative recombinant vaccines, strides in vaccine research, a shift from treatment to disease prevention, research and development of vaccines powered by AI, and enhanced identification of biomarkers for shingles susceptibility.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20264
What Are the Different Shingrix (Zostavax) Market Segments?
The shingrix (zostavax) market covered in this report is segmented -
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
What Are the Primary Drivers Shaping the Shingrix (Zostavax) Market?
The continuous increase in vaccine use is anticipated to drive the expansion of the shingrix (zostavax) market. Vaccination is the procedure of administering a vaccine to trigger the body's immune response to recognize and counter particular pathogens. The surge in vaccine use can be associated with heightened knowledge about its efficiency in preventing illnesses, lessening the burden of diseases, and creating secure and readily available vaccines. Public health efforts, enhanced healthcare facilities, and worldwide immunization programs also promote its universal acceptance. Shingrix (Zostavax) serves as an effective immunization measure by providing potent protection against shingles and its complications. It's particularly advantageous for adults over the age of 50, substantially decreasing the likelihood of shingles recurrence and post-herpetic neuralgia. For example, in May 2024, a study by the Journal of the American Medical Association (JAMA) revealed that shingles vaccinations covered by Medicare Part D rose by 46% in the year following the introduction of the IRA policy in January 2023. Furthermore, in 2022, the Australian Government Department of Health and Aged Care confirmed that COVID-19 vaccines were made freely available to all Australians. By mid-2022, over 34 million initial vaccines and boosters were given, with general practices playing a substantial part in the distribution, particularly in rural areas. Therefore, the continuous rise in vaccine use is projected to drive the shingrix (zostavax) market's growth.
Which Companies Are Leading in the Shingrix (Zostavax) Market?
Major companies operating in the shingrix (zostavax) market are GSK plc
What Are the Major Trends Shaping the Shingrix (Zostavax) Market?
One main trend in the shingrix (zostavax) market involves the development of cutting-edge products such as the non-live, recombinant subunit adjuvanted vaccines. These are developed to boost vaccine efficiency and respond to age-induced immune degeneration in high-risk groups. The non-live, recombinant subunit adjuvanted vaccine includes specific protein parts of a pathogen paired with an adjuvant to increase the immune response. For example, in September 2024, the shingles vaccine Shingrix was introduced by UK-based biopharma firm, GSK plc. The Recombinant Zoster Vaccine (RZV) - a non-live vaccine, offers up to 97% effectiveness in preventing shingles and post-herpetic neuralgia. It is created for application in adults aged 50+ and immunocompromised individuals aged 18+, through two intramuscular doses. RZV in the ZOE-50 study demonstrated up to 97% efficiency in adults over the age 50 for three years, and latest data shows over 80% effectiveness extending 6-10 years after the vaccination.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
What Are the Top Revenue-Generating Geographies in the Shingrix (Zostavax) Market?
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Shingrix (Zostavax) Market?
2. What is the CAGR expected in the Shingrix (Zostavax) Market?
3. What Are the Key Innovations Transforming the Shingrix (Zostavax) Industry?
4. Which Region Is Leading the Shingrix (Zostavax) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments."
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Shingrix (Zostavax) Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities here
News-ID: 4066421 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for Shingrix
In-Depth Analysis of the Shingrix Zostavax Market: Growth Opportunities, Key Tre …
What industry-specific factors are fueling the growth of the shingrix zostavax market?
The Shingrix (Zostavax) market is also set to grow, driven by the increasing adoption of vaccination globally. Growing awareness of the effectiveness of vaccination in preventing diseases, combined with public health initiatives and improved healthcare infrastructure, is boosting vaccination rates. Shingrix, which protects against shingles, is particularly important for adults over 50, reducing the risk of shingles recurrence and…
In-Depth Analysis of the Shingrix (Zostavax) Market: Growth Opportunities, Key T …
What Are the Projected Growth and Market Size Trends for the Shingrix (Zostavax) Market?
The market size for shingrix (zostavax) has seen an increase of $XX (CAGR) in the latest years. The market is expected to surge from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. The growth seen in the previous period is due to factors such as enhanced vaccine…
Shingles Vaccine Market Demand Will Reach a Value of USD 6.02 Billion by the Yea …
Anticipated Growth in Revenue:
Shingles Vaccine Market was valued at USD 3.06 Billion in 2022, and it is expected to reach USD 6.02 Billion by 2029, exhibiting a CAGR of 10.1 % during the forecast period (2023-2029)
Shingles Vaccine Market Overview:
The Shingles Vaccine Market is witnessing significant growth due to the increasing awareness of the severe complications associated with shingles, such as postherpetic neuralgia (PHN). Shingrix, a recombinant zoster vaccine, has become…
Shingles Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)
Shingles Vaccines Market
Shingles Vaccines Market Anticipates Robust Growth with a Projected CAGR of 10.00% from 2024 to 2031
The global Shingles Vaccines Market is poised for substantial expansion, estimated to achieve a Compound Annual Growth Rate (CAGR) of 10.00% during the forecast period spanning from 2023 to 2030.
Recommended in established nations such as the US, Canada, Germany, and the UK, the shingles vaccine is integral to National Immunisation Programs (NIP) in…
Shingles Vaccine Market is expected to See Huge Growth by 2023-2030 with Top Pla …
Description:
The Zostavax vaccine is a live attenuated vaccine that contains a weakened form of the herpes zoster virus, which causes shingles. The vaccine works by stimulating the body's immune system to produce a protective response against the virus, thereby reducing the risk of developing shingles. The effectiveness of the Zostavax vaccine varies depending on the age group. According to clinical trials, the vaccine was found to be 64% effective in…
Global Shingles Vaccine Market 2020 - 2026 | Opportunity By Top Players China ap …
CMI Present a published report on "Global Shingles Vaccines Market Industry Analysis, Growth and Forecast 2020 - 2026" delivering key insights and providing a competitive advantage to clients through a detailed report. The Shingles Vaccines Market is the foundation of the improvement edges and prospects, as the progression of an explicit plan needs various imaginatively maintained theory, musings, and methodologies. The report contains exhibit on current market analysis scenario, upcoming…
